Acupath Names Hillel Kahane, MD as Chief Medical Officer & Director of Uropathology
PLAINVIEW, N.Y., Oct. 22, 2018 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic pathology services, announces the addition of Hillel Kahane, MD as the company's Chief Medical Officer and Director of Uropathology. Prior to Acupath, Dr. Kahane served as Medical Director of Bostwick Labs from 2007 – 2018, and as Executive Medical Director of Dianon Pathology (LabCorp) from 2000 – 2007.
As CMO, Dr. Kahane joins John Cucci (Chief Sales Officer), Zaleena Neice (Chief Financial Officer), and Steve Kamalic (Chief Operating Offer) on the Acupath Labs Executive Committee and will help guide the company's overall strategy and vision.
In addition, Dr. Kahane will serve as Director of Uropathology and will be responsible for overseeing the company's rapidly growing uropathology department and spearheading the company's continued expansion nationwide.
"I am thrilled to join the team at Acupath and look forward to building on the significant success achieved in recent years. Having interpreted over 1,000,000 prostate biopsies in my 25+ year career in the uropathology industry, I look forward to working with urologists and pathologists across the country to offer patients the highest quality care available in the industry," said Dr. Kahane.
"We are fortunate to have Dr. Kahane on our team and look forward to attending the LUGPA (Large Urology Group Practice Association) conference on November 1st & 2nd to meet with the premier urology practices across the country and discuss how Acupath can help their practices enhance patient care," said The Executive Committee in a statement.
About Acupath Laboratories, Inc.
Founded in 1998 and based in Plainview, NY (Long Island), Acupath is a provider of sub-specialized anatomic pathology services focused on the following specialties; Urology, Gastroenterology, Dermatology, Women's Health, Otolaryngology, Podiatry, and Hematology / Oncology. Acupath offers an extensive test menu on both a global and TC/PC basis, processes well over 150,000 specimens annually, and is one of the leading providers of cutting edge FISH testing for the detection of bladder cancer (UroVysion™ Abbott Molecular), prostate cancer (PTEN ERG), breast cancer (HER-2), and esophageal cancer (Barrett's esophagus FISH).
Contact:
Hillary Garcia
Media Relations
516-775-8103
[email protected]
SOURCE Acupath Laboratories, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article